ServisFirst: Q2 Earnings Snapshot
On a per-share basis, the Birmingham, Alabama-based company said it had profit of $1.12. Earnings, adjusted for one-time gains and costs, came to $1.21 per share.
The holding company for ServisFirst Bank posted revenue of $255.6 million in the period. Its adjusted revenue was $140.7 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 minutes ago
- Business Wire
Benfica Unveils Bold New Vision and Masterplan for Estádio da Luz and Surrounding Precinct with World-Class Fan and Community Facilities
LISBON, Portugal--(BUSINESS WIRE)--S.L. Benfica has unveiled a transformative new masterplan for Estádio da Luz, positioning the stadium as a premier international sports and entertainment destination – aligning it with the most exciting developments of its kind around the world – while enhancing the fan experience and strengthening its connection with both supporters and the local community. S.L. Benfica unveils its transformative new masterplan for Estádio da Luz, positioning the stadium as a premier international sports and entertainment destination – aligning it with the most exciting developments of its kind around the world. Share Populous has led all aspects of the masterplan design in collaboration with the renowned Lisbon-based architecture firm Saraiva + Associados. Populous also served as the original designer of the stadium, which opened in 2004. A World-Class District for Sports, Culture and Entertainment The project will modernise the stadium's facilities and introduce new venues, amenities and public spaces to the surrounding precinct, creating a valuable civic asset for the people of Benfica and supporting the club's long-term financial sustainability. The masterplan includes: A 10,000-capacity multi-purpose indoor arena, capable of hosting concerts, cultural events, esports and major sporting events. Two state-of-the-art indoor sports halls with capacities of 2,500 and 1,500 seats respectively, adaptable for basketball, volleyball, boxing and more that replace the current pavilions and swimming pool A new community swimming pool (25x25m) with modern amenities, offering a recreational resource for fans and residents alike. A new theatre and events space, holding up to 500 people. An outdoor rooftop football pitch and a running track, creating immersive training and fitness environments in the heart of Lisbon. Commercial and residential facilities Enhanced Fan Experience at the Core Benfiquistas – as the club's supporters are known – will enjoy a new pre- and post-match gathering space in the form of a 100m x 40m fan plaza in front of the stadium's main façade, inspired by Lisbon's famed civic squares such as Praça do Rossio. With capacity for over 10,000 fans, the plaza will feature a DJ deck and event space, and will be surrounded by food and beverage outlets, retail and terraced restaurants – establishing it as a year-round destination for the city. Supporters will also benefit from a range of enhancements across the campus, including hospitality terraces, large-format sky-screen installations, and improved connectivity bridges to enhance movement and accessibility. The statue of Eusébio – a beloved icon of the club – will be carefully relocated to stand at the main entrance to the plaza, prominently positioned against the backdrop of the stadium's façade to greet fans as they arrive. Modernisation of the Estádio da Luz The project will also refresh and reinvigorate the stadium itself. A new façade – fluid and dynamic in its architecture – redefines the stadium's form through a contemporary lens, tempering light and heat to provide shade for the concourses and enhance fan comfort, while preserving the building's iconic curved roof trusses. The facade features integrated LED lighting that weaves a dynamic digital layer across the entire structure, illuminating the architecture on matchdays. It transforms the stadium into both a beacon for supporters and an immersive backdrop for the fan plaza. This programmable LED 'skin' also allows the stadium to adapt effortlessly to a wide range of events, from football matches to concerts. Michael Forward, Associate Principal at Populous and Lead Designer for the project, explains: 'The stadium façade articulates a contemporary architectural language rooted in Lisbon's evolving urban narrative. A restrained palette of neutral tones fosters a seamless dialogue with the surrounding masterplan, while vertical louvres lend both rhythm and porosity to the envelope. The overall effect pays homage to Benfica's heritage while creating a striking visual effect looking confidently to the future.' Additionally, a new fourth level will be added to the stadium, outside the seating bowl, providing 6,800 sqm of mixed-use space that includes the potential for club offices, an increased-capacity premium hospitality offering and commercial facilities. This extension is part of a wider strategy to activate the stadium beyond matchdays and embed it more deeply in Lisbon's urban life. Sustainability and Legacy The project champions sustainable design principles, integrating photovoltaic panels on the arena roof, 'green' roofs, rainwater harvesting and landscape strategies that support ecological resilience. The development is designed not only to enhance the matchday experience but to provide long-term social and environmental benefits to the Lisbon community. Quotes: Rui Costa, President of S.L. Benfica, said: 'This is an ambitious and strategic project, focused on our members, fans, and the continued growth of the club, which we intend to begin implementing immediately. Our aim is to enhance the stadium and wider masterplan facilities to support all sports and further strengthen Benfica's position, both in Portugal and around the world, as the country's leading sporting institution – with completion in time for the major international competitions that Portugal will host. It is a project in the true Benfica spirit – one that enhances the competitive environment, deepens the club experience, and welcomes all those who want to experience what it means to be part of the Chama Imensa, the greatest in Portugal. It is a commitment to make us stronger, more valuable, and an even greater leader.' Tom Jones, Senior Principal and Project Architect, said: 'This masterplan is an example of how venue-anchored mixed-use developments can reinvigorate a whole district, and sets a new benchmark for how stadiums can serve as cultural and community beacons. Estádio da Luz will not just be a home for Benfica's proud history, but a catalyst for its vibrant future.' Jorge Betancor, Principal at Populous, who leads the firm's operations in Portugal, said: 'The Estádio da Luz is one of Portugal's and Europe's most iconic stadiums. This project will modernise its facilities and create new amenities within the precinct for both spectators on matchdays and the public year-round – aligning it with developments such as Wembley Stadium and Manchester City's Etihad Stadium. It will set a new benchmark in Portugal and at an exciting juncture in the country's sporting development as it builds towards World Cup 2030.' About Populous Populous is a global architecture and design practice specialising in the design of sports and entertainment venues. The firm's portfolio includes Benfica's Estádio da Luz, Tottenham Hotspur Stadium and Wembley Stadium in the UK, along with stadium-anchored masterplans such as Casablanca Stadium in Morocco - set to become the largest football stadium in the world – and Kai Tak Sports Park in Hong Kong. Over the last 40 years, the practice has designed more than 3,500 projects worth over $60 billion across emerging and established markets. Populous' comprehensive services include architecture, interior design, event planning and overlay, brand activation, wayfinding, urban design, food & beverage strategy, landscape architecture and sustainable design consulting. Populous has over 1,500 staff and 31 offices on four continents, with regional centres in London, Kansas City and Brisbane.
Yahoo
5 minutes ago
- Yahoo
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive. All three companies have attractive prospects beyond that. 10 stocks we like better than Eli Lilly › Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts. Putting aside the fact that it's impossible to predict the outcome of a clinical trial beforehand, even when the results are up to Wall Street's standards, it's hardly worth investing in the company unless there are other good reasons to think it will perform well over long periods. That's why you may want to take a closer look at Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). All three drugmakers should release results from key clinical trials within the next 18 months, and all three have strong prospects for the next five years at least. 1. Eli Lilly In April, Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron. While the market reacted positively to this development, the study in question focused on diabetes patients and used A1c reduction as its primary endpoint. All eyes will be on the company's ongoing late-stage studies for orforglipron in obesity; it should release data from at least one of those clinical trials within the next year. Eli Lilly's work in weight management has taken center stage in the past few years. The pharmaceutical leader could, once again, make a breakthrough by being one of the first to launch a highly effective oral GLP-1 anti-obesity drug. Since current options are administered subcutaneously, you can expect orforglipron to reach a reasonable level of success on the market -- but that's only if it performs well in phase 3 obesity studies. If it fails to do so, Lilly's shares could plunge. Even so, the stock should still be a buy. True, orforglipron would strengthen Lilly's already robust lineup. But even if it falls short of expectations in late-stage studies, the company has several other candidates in development, including retatrutide, which is also in phase 3 trials. Meanwhile, Lilly continues to generate consistent financial results. Revenue and earnings have been growing at a good clip, and that should continue for the foreseeable future. Lastly, Eli Lilly is an excellent dividend growth stock. Although results from phase 3 trials for orforglipron in obesity will be important to monitor, the stock should perform well over the long run, regardless of the outcome of these trials. 2. Summit Therapeutics Summit Therapeutics is developing ivonescimab, a cancer medicine it licensed from Akeso, a China-based biopharma. Ivonescimab is already approved in China; however, Summit needs to conduct clinical trials elsewhere to support approval in the U.S., Europe, and other regions where it holds marketing rights. At least one of these studies will be of particular interest to investors. Summit is testing its crown jewel in a late-stage trial against Merck's Keytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study is ongoing, and there is a good chance we'll see top-line data from it by the end of next year. Summit's stock soared when it reported that ivonescimab did better than Keytruda at reducing the risk of recurrence or death in NSCLC patients, in a study conducted in China. However, reproducing this result elsewhere could, once again, jolt the stock price. On the flip side, Summit's share price will move in the wrong direction if the results aren't what Wall Street expects. Should you buy the stock? To me, Summit Therapeutics' prospects for the next five years seem attractive. Ivonescimab is being tested across a range of different cancers, and it looks highly promising in NSCLC, which could be its most important market. Even with the possibility that it may not perform as well in studies outside of China, having already been approved by regulatory authorities in one region reduces the risk of significant clinical and regulatory setbacks. Ivonescimab looks like a potential pipeline in a drug. And if you invest in Summit Therapeutics now, you might reap the benefits of its leading candidate's potential. 3. Vertex Pharmaceuticals Vertex Pharmaceuticals is a proven innovator. The company's strategy is to develop breakthrough medicines where there's a high unmet need. One of Vertex's new targets is type 1 diabetes (T1D). There are no cures for this chronic disease, but the biotech's candidate zimislecel could be a functional cure, in the sense that it could recover patients' ability to produce their own insulin -- something that people with T1D can't do. In the phase 1/2 portion of an ongoing phase 1/2/3 clinical trial, 10 of 12 patients who received zimislecel were insulin-free after a one-year follow-up. All 12 were free of severe hypoglycemic events after 90 days. Vertex should have data from the late-stage portion of this ongoing clinical trial within the next year. Positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a nice addition to Vertex's portfolio. The biotech remains the leader in the market for drugs that treat the underlying genetic causes of cystic fibrosis, a business that is still helping it drive strong revenue and earnings growth. Furthermore, Vertex has added several medicines to its portfolio over the past five years, including Journavx for acute pain and Casgevy for two rare blood-related disorders. Vertex Pharmaceuticals' pipeline also has promising programs beyond zimislecel. Well beyond the announcement of clinical-trial results for this promising T1D therapy, the stock will be in an excellent position to perform. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Dogecoin Retreats Despite Bit Origin's $500M Allocation, RSI Hits Overbought
Dogecoin tumbled nearly 7% over the past 24 hours, reversing gains after briefly touching the $0.29 level — its highest price in over 10 months. The decline comes despite Bit Origin's headline-grabbing $500 million DOGE treasury allocation, which included over 40 million tokens acquired this week. Traders cited overbought conditions and lack of sustained buy pressure as key reasons for the retracement. DOGE is now consolidating just above the $0.26 mark. News Background Bit Origin, a Hong Kong-based commodities and treasury firm, announced a major corporate commitment to Dogecoin with a $500 million treasury strategy involving a phased purchase of 1 billion DOGE. The move was initially seen as a validation of DOGE as a corporate asset. However, price failed to hold highs above $0.29, raising questions over DOGE's ability to sustain institutional rallies amid broader market headwinds and historically volatile trading conditions. Price Action Summary • DOGE surged to $0.29 at 17:00 on July 21 following news of Bit Origin's treasury plan, before falling to $0.27 by session close.• The 24-hour trading range spanned $0.26–$0.29, marking a 9% volatility window.• Final-hour trading (03:06–04:05 UTC on July 22) saw DOGE drop from $0.27 to $0.26, its lowest since Thursday, with volume rising to 37.2 million during the decline.• DOGE is now down 7% from session highs, despite institutional buying. Technical Analysis • RSI spiked to 85.95 on the move to $0.29, indicating overbought conditions.• Trading volumes peaked at 1.703 billion tokens during the breakout, nearly 2.5x the daily average.• Resistance remains firm at $0.29 with repeated rejections.• Support weakened from $0.27 to $0.26 as buyers failed to hold levels.• DOGE now trades at the lower end of its recent range, risking further downside if $0.26 fails. What Traders Are Watching Traders are eyeing whether DOGE can hold above $0.26, which has served as short-term support amid institutional flows. Failure to hold this level may trigger a retest of the $0.245-$0.25 zone. Any renewed buying from corporate treasuries or ETF-related speculation may help DOGE reclaim the $0.275-$0.29 resistance band — but momentum remains fragile.
